RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer’s disease biomarkers in the eye.

Our goal is to enable widespread early detection of Alzheimer’s disease with accessible and scalable screening.

In a quick eye exam, RetiSpec  opens a window of opportunity for timely and specific therapeutic interventions, so the progression of the disease may be slowed or even prevented. 

RetiSpec’s patented technology harnesses Hyperspectral Imagery in synergy with machine-learning to allow for rapid, simple, and cost-effective identification of Alzheimer’s biomarkers years before the emergence of clinical symptoms. 

RetiSpec is using computer vision and machine-learning algorithms to detect unique signatures of Alzheimer’s biomarkers in a manner of seconds


CEO & Co-founder
Lead Scientist
Data Scientist
Head of Clinical Operations & Partnerships
COO & Co-founder
Ocular Imaging Specialist

RetiSpec Receives Award from Alzheimer's Drug Discovery Foundation (ADDF)

Oct 08, 2019

Howard Fillit, M.D., Founding Executive Director and Chief Science Officer of ADDF, said, "We believe that RetiSpec's retinal scanner stands out and shows promise as a unique diagnostic tool among a range of technologies in development. The technology has the potential to facilitate early diagnosis, improve the lives of patients and their loved ones and save the healthcare system money and resources. The technology will also be useful in making clinical trials for Alzheimer's disease more efficient."


University of Minnesota collaborates with medical imaging startup RetiSpec 

October 17, 2018

The University’s collaboration with RetiSpec comes following a successful pilot clinical study demonstrating the capabilities of the technology, involving 31 participants both with and without Alzheimer’s. 

From the Lab to Life: A Retinal Scanner for Early Detection of Alzheimer’s Disease

July 17, 2018

Ontario Brain Institute backed RetiSpec to accelerate growth in Ontario, Canada. RetiSpec has developed software and “plug and play” hardware components that can be applied directly to existing retinal cameras readily found in optometrists’ offices.

An Eye Scan For Alzheimer's? Toronto Memory Program is Looking Into It (CTV NEWS) 

Sep 24, 2019

An Eye Scan For Alzheimer's? Toronto Memory Program Is Looking Into It.

Dr. Sharon Cohen discuss the RetiSpec technology and the study conducted at Toronto Memory Program.

Screen Shot 2019-07-28 at 9.38.34 PM.png

Announcement of RetiSpec's Clinical Study in Israel

April 3, 2018

The clinical study at Sheba Medical Centre will begin in January 2019 and will investigate the RetiSpec technology to detect individuals with early signs of Alzheimer's Disease compared to current modalities.


Could an eye scan be used to diagnose Alzheimer's disease?

August 6, 2019

A Toronto clinic is first in the world to test retina scans that may be able to diagnose Alzheimer's disease using a hypersensitive device developed in Canada.


CABHI is working with RetiSpec to accelerate its technology in Ontario and Canada 

March 04, 2019

The CABHI-funded RetiSpec trial will determine the safety and effectiveness of the technology through human clinical testing, and help spur commercialization of the technology in Ontario and Canada – to get it into the hands of those who need it most.


If you are interested in partnering with RetiSpec,

please contact us at hello@retispec.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon

Toronto, ON, Canada

© 2019 RetiSpec Inc. All rights reserved.